Marty Makary resigned as commissioner of the US Food and Drug Administration on Tuesday after 13 months in the role, concluding a turbulent tenure during which he clashed with the White House, Congress, industry groups and the public — most recently over the regulation of fruit-flavored vaping products.
Marty Makary stepped down as head of the US Food and Drug Administration on Tuesday, ending a contentious 13-month run as the nation's top food, drug, tobacco and medical device regulator, according to reports from Politico, Reuters and NBC News.
Kyle Diamantas, who previously served as the FDA's senior food official responsible for setting the strategic direction and operations of US food policy, will step in as acting commissioner, Politico reported, which first broke the news of the resignation.
A Tenure Defined by Conflict
Makary's time at the FDA was marked by repeated friction across multiple fronts. The White House, members of Congress, industry stakeholders and public health advocates all raised concerns during his leadership — a rare breadth of opposition that ultimately contributed to his departure.
Among the most recent flashpoints was a reported dispute with the Trump administration over fruit-flavored vaping products. The Guardian reported that Makary clashed with the White House on the issue, which has long divided public health advocates — who argue flavored vapes are a gateway to nicotine addiction for minors — and industry groups, who contend such products help adult smokers transition away from cigarettes.
The FDA, under Makary, also navigated a demanding regulatory environment at a time when the agency faced significant budgetary and staffing pressures following broader federal workforce reductions under the Department of Government Efficiency.
Diamantas Takes the Helm
Diamantas's background in food policy positions him as a familiar, if transitional, figure for agency staff. His appointment as acting commissioner signals continuity on the food-regulation side of the FDA's mandate, though his stance on pharmaceutical approvals, tobacco products and other contested areas has yet to be tested at the commissioner level.
The FDA oversees a vast regulatory portfolio affecting nearly every American, from the safety of the food supply and the approval of prescription drugs to the regulation of medical devices and tobacco products — a scope that has historically made the commissioner's role one of the most consequential in federal public health administration.
As of publication, the White House had not formally announced a nominee for a permanent replacement.
Analysis
Why This Matters
- The FDA commissioner oversees regulatory decisions affecting food safety, drug approvals, medical devices and tobacco — areas that touch virtually every American's daily life. Leadership instability can delay or distort those decisions.
- Makary's resignation over a politically charged issue like flavored vapes signals that the Trump administration is willing to remove agency heads who resist White House direction, raising questions about the independence of federal regulators.
- An acting commissioner lacks the confirmed authority and political capital of a Senate-confirmed leader, which may limit the agency's ability to take bold or controversial regulatory action in the short term.
Background
Marty Makary, a surgeon and public health commentator, was confirmed as FDA commissioner in early 2025 under the Trump administration. He came to the role with a reputation for skepticism of institutional medicine and a willingness to challenge regulatory orthodoxy, which initially aligned with the administration's deregulatory instincts.
The FDA has long been a politically sensitive agency, often caught between industry pressure for faster approvals and public health advocates demanding rigorous safety standards. In recent years, controversies over opioid approvals, COVID-19 policy and tobacco regulation had already strained the agency's credibility with parts of the public.
The flavored vape debate has been simmering for years. The FDA under previous administrations moved to restrict fruit and candy-flavored e-cigarettes after evidence suggested they were attracting underage users. The Trump administration has faced competing pressures from the vaping industry — a significant economic constituency — and public health groups alarmed by youth nicotine addiction rates.
Key Perspectives
The White House: Administration officials reportedly pushed Makary on the flavored vape issue, suggesting the White House favored a more permissive approach that aligned with industry interests and reflected the administration's broader deregulatory agenda.
Public Health Advocates: Groups focused on youth health have consistently opposed fruit-flavored vaping products, arguing they are designed to appeal to minors and undermine decades of progress in reducing tobacco use among young people.
Critics/Skeptics: Some observers warn that a politically driven resignation — particularly over a product regulation question — sets a troubling precedent for FDA independence. If commissioners can be pressured out over commercially sensitive decisions, the agency's ability to make science-based rulings free from political interference may be compromised.
What to Watch
- Whether the Trump administration nominates a permanent FDA commissioner quickly, and what that nominee's record on pharmaceutical approval timelines and tobacco regulation signals about the agency's future direction.
- How acting commissioner Diamantas handles the pending flavored vape decisions, which will indicate whether the White House has achieved its desired policy shift through the leadership change.
- Congressional oversight hearings, which may probe the circumstances of Makary's departure and examine whether political interference in FDA regulatory decisions occurred.